8-K: AVITA Medical Expands Portfolio with Exclusive Dermal Matrix Agreement

AVITA Medical has secured an exclusive five-year agreement with Regenity Biosciences to market and distribute a collagen-based dermal matrix, pending FDA 510(k) clearance.

Summary

• AVITA Medical has entered into a five-year exclusive agreement with Regenity Biosciences for a collagen-based dermal matrix.
• The agreement grants AVITA Medical exclusive rights to market, sell, and distribute the product in the U.S., and potentially in the EU, Australia, and Japan.
• Regenity is expected to secure FDA 510(k) clearance for the product in the fourth quarter of 2024.
• AVITA Medical will make payments totaling up to $5.0 million to Regenity, with $2.0 million upon 510(k) clearance and $3.0 million contingent on positive clinical study results by January 4, 2026.
• The revenue sharing agreement starts at 50% of the average sales price for the first two years, increasing to 60% in subsequent years.
• Clinical studies are planned for 2025 to evaluate the new dermal matrix in full-thickness wounds, both with and without RECELL.

Sentiment

Score: 8

Explanation: The document is positive due to the strategic partnership, potential for revenue growth, and expansion of the product portfolio. The risks are manageable and the company has a clear plan for clinical studies and market entry.

Positives

• The agreement expands AVITA Medical's product portfolio with a new dermal matrix.
• The exclusive distribution rights cover key markets including the U.S., EU, Australia, and Japan.
• The revenue sharing agreement provides a strong incentive for AVITA Medical with a 60% share after the first two years.
• The new product has the potential to establish a new standard of care in wound treatment when used with RECELL.
• The agreement includes potential for future enhancements and modifications to the product.

Negatives

• The $3.0 million payment is contingent on positive results from clinical studies, which introduces uncertainty.
• The initial revenue share is 50%, which is lower than the future 60% share.
• The agreement is dependent on Regenity securing FDA 510(k) clearance, which is not guaranteed.

Risks

• The FDA 510(k) clearance for the dermal matrix is not guaranteed and could be delayed.
• Clinical study results may not be positive, which could impact the $3.0 million payment and the agreement extension.
• The success of the product depends on market acceptance and the ability to integrate it with existing RECELL technology.
• There are risks associated with the development and manufacturing of the product by Regenity.

Future Outlook

The company anticipates completing clinical studies in 2025 and aims to establish a new standard of care with a one-stage closure using the new dermal matrix and RECELL technology.

Management Comments

• Jim Corbett, Chief Executive Officer of AVITA Medical, stated that the collaboration significantly strengthens their portfolio and advances their long-term growth objectives.
• Jim Corbett also mentioned that integrating Regenity's collagen-based solutions with their existing RECELL technology has the potential to establish a new standard of care with a one-stage closure, improving patient outcomes.

Industry Context

This agreement aligns with the growing trend in regenerative medicine and advanced wound care, where companies are seeking innovative solutions to improve patient outcomes and reduce treatment times. The use of collagen-based dermal matrices is a well-established approach in this field.

Comparison to Industry Standards

• Companies like Integra LifeSciences and Organogenesis also offer dermal matrices for wound care, but AVITA Medical's approach combines a new matrix with their existing RECELL technology, potentially offering a unique advantage.
• The 50/60% revenue share agreement is competitive within the industry, where distribution agreements often involve similar tiered structures.
• The planned clinical studies are in line with industry best practices for evaluating new wound care products, with a focus on demonstrating improved time to grafting and wound closure.

Stakeholder Impact

• Shareholders will benefit from the potential revenue growth and expanded product portfolio.
• Patients may benefit from improved wound care outcomes and reduced treatment times.
• Employees may see increased opportunities due to the company's growth.
• Suppliers may see increased demand for materials related to the new product.

Next Steps

• Regenity will work to secure FDA 510(k) clearance for the dermal matrix in the fourth quarter of 2024.
• AVITA Medical will initiate multiple clinical studies in 2025 to evaluate the new dermal matrix.
• AVITA Medical will prepare for the commercial launch of the new dermal matrix upon FDA clearance.

Key Dates

Keywords

dermal matrix, wound care, regenerative medicine, collagen, distribution agreement, 510(k) clearance, RECELL, Regenity Biosciences, AVITA Medical